NASDAQ:VCEL - Vericel Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$11.00 +0.05 (+0.46 %)
(As of 06/22/2018 04:00 PM ET)
Previous Close$11.00
Today's Range$10.15 - $11.0001
52-Week Range$2.85 - $14.75
Volume6.34 million shs
Average Volume1.32 million shs
Market Capitalization$401.66 million
P/E Ratio-22.00
Dividend YieldN/A
Vericel logoVericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies to repair and regenerate damaged tissues and organs. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Carticel, an autologous chondrocyte implant for the repair of symptomatic cartilage defects of the femoral condyle caused by acute or repetitive trauma in patients that have inadequate response to a prior arthroscopic or other surgical repair procedure. The company also markets Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. In addition, it develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.

Receive VCEL News and Ratings via Email

Sign-up to receive the latest news and ratings for VCEL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic


Debt-to-Equity Ratio0.75
Current Ratio3.48
Quick Ratio3.19


Trailing P/E Ratio-22.00
Forward P/E Ratio-29.73
P/E GrowthN/A

Sales & Book Value

Annual Sales$63.92 million
Price / Sales6.31
Cash FlowN/A
Price / CashN/A
Book Value$0.65 per share
Price / Book16.92


EPS (Most Recent Fiscal Year)($0.50)
Net Income$-17,280,000.00
Net Margins-20.89%
Return on Equity-67.15%
Return on Assets-27.10%


Outstanding Shares36,680,000

The Truth About Cryptocurrencies

Vericel (NASDAQ:VCEL) Frequently Asked Questions

What is Vericel's stock symbol?

Vericel trades on the NASDAQ under the ticker symbol "VCEL."

How were Vericel's earnings last quarter?

Vericel Corp (NASDAQ:VCEL) issued its quarterly earnings data on Tuesday, May, 8th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.13) by $0.08. The biotechnology company had revenue of $18.03 million for the quarter, compared to the consensus estimate of $16.51 million. Vericel had a negative net margin of 20.89% and a negative return on equity of 67.15%. View Vericel's Earnings History.

When is Vericel's next earnings date?

Vericel is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Vericel.

What price target have analysts set for VCEL?

5 Wall Street analysts have issued 12-month price objectives for Vericel's shares. Their predictions range from $14.00 to $17.00. On average, they anticipate Vericel's stock price to reach $15.25 in the next twelve months. View Analyst Ratings for Vericel.

Who are some of Vericel's key competitors?

Who are Vericel's key executives?

Vericel's management team includes the folowing people:
  • Mr. Dominick C. Colangelo, CEO, Pres & Director (Age 54)
  • Mr. Gerard J. Michel, CFO & VP of Corp. Devel. (Age 55)
  • Mr. Daniel R. Orlando, Chief Operating Officer (Age 53)
  • Ms. Jacquelyn Fahey Sandell, VP, Gen. Counsel & Corp. Sec.
  • Ms. Heidi Hassen, Sr. Director of HR

Has Vericel been receiving favorable news coverage?

Press coverage about VCEL stock has trended somewhat positive this week, Accern reports. The research group rates the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Vericel earned a news sentiment score of 0.04 on Accern's scale. They also gave news articles about the biotechnology company an impact score of 45.48 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are Vericel's major shareholders?

Vericel's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Archon Capital Management LLC (6.52%), PNC Financial Services Group Inc. (1.73%), Millennium Management LLC (1.69%), First Washington CORP (1.52%), Next Century Growth Investors LLC (1.01%) and Russell Investments Group Ltd. (0.87%). Company insiders that own Vericel stock include Alan L Rubino, Daniel Orlando, Dominick Colangelo and Paul K Wotton. View Institutional Ownership Trends for Vericel.

Which major investors are selling Vericel stock?

VCEL stock was sold by a variety of institutional investors in the last quarter, including Archon Capital Management LLC, First Washington CORP, Alpine Global Management LLC and Dorsey & Whitney Trust CO LLC. Company insiders that have sold Vericel company stock in the last year include Daniel Orlando, Dominick Colangelo and Paul K Wotton. View Insider Buying and Selling for Vericel.

Which major investors are buying Vericel stock?

VCEL stock was bought by a variety of institutional investors in the last quarter, including PNC Financial Services Group Inc., Millennium Management LLC, Next Century Growth Investors LLC, Russell Investments Group Ltd., Timpani Capital Management LLC, EAM Global Investors LLC, JPMorgan Chase & Co. and Tibra Equities Europe Ltd. View Insider Buying and Selling for Vericel.

How do I buy shares of Vericel?

Shares of VCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vericel's stock price today?

One share of VCEL stock can currently be purchased for approximately $11.00.

How big of a company is Vericel?

Vericel has a market capitalization of $401.66 million and generates $63.92 million in revenue each year. The biotechnology company earns $-17,280,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Vericel employs 205 workers across the globe.

How can I contact Vericel?

Vericel's mailing address is 64 SIDNEY ST., CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 800-556-0311 or via email at [email protected]

MarketBeat Community Rating for Vericel (VCEL)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  185 (Vote Outperform)
Underperform Votes:  173 (Vote Underperform)
Total Votes:  358
MarketBeat's community ratings are surveys of what our community members think about Vericel and other stocks. Vote "Outperform" if you believe VCEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VCEL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/23/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.